XWXi Wu

Xi Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xi Wu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Tingting Xu

    Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    2 shared publications
  • Yongqian Shu

    Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

    2 shared publications
  • Dong Hua

    School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China; Department of Oncology, Wuxi People's Hospital, Wuxi 214023, China; Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China; Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China

    1 shared publication
  • Duo Xu

    Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

    1 shared publication
  • Huiyao Li

    The Affiliated Children's Hospital of Jiangnan University, Wuxi Children's Hospital, Wuxi School of Medicine, Jiangnan University, Wuxi, China

    1 shared publication
  • Jiahua Cui

    Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    1 shared publication

Latest Publications

  • Open Access

    Bridging the gap: ferroptosis of immune cells in the tumor microenvironment

    by Weijing Wang, Huiyao Li, Shuai Liang, Yani Hu, Junli Ding, Xi Wu, Dong Hua

    Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is increasingly recognized as a pivotal immunomodulatory mechanism within the tumor microenvironment (TME). Beyond its well-established role in tumor cell elimination, emerging evidence reveals that immune cell subsets exhibit distinct susceptibility to ferroptosis, with profound consequences for antitumor immunity. This review systematically delineates the dual and cell-type-specific roles of ferroptosis across innate and adaptive immune populations: while ferroptosis-mediated depletion of immunosuppressive cells potentiates antitumor responses, immunostimulatory cells critically depend on ferroptosis defense pathways to sustain their survival and function—their dysfunction exacerbates immune evasion. We further decode the metabolic and signaling networks that govern immune cell ferroptosis and their dynamic interplay with immunotherapy and engineered nanomaterials. Finally, we critically addressed key challenges in clinical translation, including biomarker development, cell-specific delivery, and design of nanomaterials to minimize off-target effects. By elucidating the immune context-dependence of ferroptosis, this review provides a framework for developing precision therapies that harness ferroptosis-immune crosstalk to improve cancer therapy in the clinic.


  • Open Access

    The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications

    by Yunru Gu, Yuan Fang, Xi Wu, Tingting Xu, Tong Hu, Yangyue Xu, Pei Ma, Qiang Wang, Yongqian Shu

    Tumor initiation, progression, and response to therapies depend to a great extent on interactions between malignant cells and the tumor microenvironment (TME), which denotes the cancerous/non-cancerous cells, cytokines, chemokines, and various other factors around tumors. Cancer cells as well as stroma cells can not only obtain adaption to the TME but also sculpt their microenvironment through a series of signaling pathways. The post-translational modification (PTM) of eukaryotic cells by small ubiquitin-related modifier (SUMO) proteins is now recognized as a key flexible pathway. Proteins involved in tumorigenesis guiding several biological processes including chromatin organization, DNA repair, transcription, protein trafficking, and signal conduction rely on SUMOylation. The purpose of this review is to explore the role that SUMOylation plays in the TME formation and reprogramming, emphasize the importance of targeting SUMOylation to intervene in the TME and discuss the potential of SUMOylation inhibitors (SUMOi) in ameliorating tumor prognosis.


  • Open Access

    Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses

    by Duo Xu, Shengchen Liu, Xi Wu, Thomas M. Marti, Patrick Dorn, Ralph A. Schmid, Ren-Wang Peng, Yongqian Shu

    The histone H3 lysine 36 (H3K36) methyltransferase NSD3, a neighboring gene of FGFR1, has been identified as a critical genetic driver of lung squamous cell carcinoma (LUSC). However, the molecular characteristics, especially the immunological roles of NSD3 in driving carcinogenesis, are poorly understood. In this study, we systematically integrated multi-omics data (e.g., genome, transcriptome, proteome, and TMA array) to dissect the immunological profiles in NSD3-amplified LUSC. Next, pharmaco-transcriptomic correlation analysis was implemented to identify the molecular underpinnings and therapeutic vulnerabilities in LUSC. We revealed that NSD3-amplified LUSC presents a non-inflamed tumor immune microenvironment (TIME) state in multiple independent LUSC patient cohorts. Predictably, elevated NSD3 expression was correlated with a worse immunotherapy outcome. Further molecular characterizations revealed that the high activity of unfolded protein response (UPR) signaling might be a pivotal mediator for the non-immunogenic phenotype of NSD3-amplified LUSC. Concordantly, we showed that NSD3-amplified LUSCs exhibited a more sensitive phenotype to compounds targeting UPR branches than the wild-type group. In brief, our multi-level analyses point to a previously unappreciated immunological role for NSD3 and provide therapeutic rationales for NSD3-amplified squamous lung cancer.


  • Open Access

    Crosstalk between Environmental Inflammatory Stimuli and Non-Coding RNA in Cancer Occurrence and Development

    by Tingting Xu, Mengyan Xie, Xinming Jing, Jiahua Cui, Xi Wu, Yongqian Shu

    There is a clear relationship between inflammatory response and different stages of tumor development. Common inflammation-related carcinogens include viruses, bacteria, and environmental mutagens, such as air pollutants, toxic metals, and ultraviolet light. The expression pattern of ncRNA changes in a variety of disease conditions, including inflammation and cancer. Non-coding RNAs (ncRNAs) have a causative role in enhancing inflammatory stimulation and evading immune responses, which are particularly important in persistent pathogen infection and inflammation-to-cancer transformation. In this review, we investigated the mechanism of ncRNA expression imbalance in inflammation-related cancers. A better understanding of the function of inflammation-associated ncRNAs may help to reveal the potential of ncRNAs as a new therapeutic strategy.